Stay updated on Pembrolizumab in Advanced Adrenocortical Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Advanced Adrenocortical Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab in Advanced Adrenocortical Carcinoma Clinical Trial page
- Check5 days agoChange DetectedA new revision entry, v3.5.4, was added to the revision history, replacing the previous v3.5.3; this reflects an update to the page's documentation/metadata.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page’s revision/version indicator was updated from **v3.5.2** to **v3.5.3**, reflecting a change in the site’s interface or backend version rather than the underlying clinical trial information.SummaryDifference0.1%

- Check33 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check40 days agoChange DetectedUpdates to the Study Record Dates (e.g., 2026-04-06; 2026-03-23) reflect maintenance of the page's history. The core trial information remains unchanged.SummaryDifference0.3%

- Check48 days agoChange DetectedAdded Adrenal cortex carcinoma as a visible keyword/context reference and linked a Genetics and Rare Diseases Information Center resource. This provides additional background context and a direct external reference related to the study topic.SummaryDifference0.2%

- Check62 days agoChange DetectedPage revision updated to v3.5.0, replacing the previous v3.4.3.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Advanced Adrenocortical Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced Adrenocortical Carcinoma Clinical Trial page.